BLBP Is Both a Marker for Poor Prognosis and a Potential Therapeutic Target in Paediatric Ependymoma.
BLBP
FABP7
PPAR
brain tumor
docosahexanoic acid
drug resistance
ependymoma
invasion
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Apr 2021
27 Apr 2021
Historique:
received:
29
03
2021
accepted:
23
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Paediatric ependymomas are aggressive, treatment-resistant tumours with a tendency towards relapse, consistent with a sub-population of therapy-resistant cancer stem cells. These cells are believed to derive from brain lipid binding protein (BLBP)-expressing radial glia, hence we proposed that BLBP may be a marker for ependymoma therapy resistance. BLBP protein expression correlated with reduced overall survival (OS) in patients from two trials (CNS9204, a chemotherapy-led infant trial-5 y OS 45% vs. 80%,
Identifiants
pubmed: 33925302
pii: cancers13092100
doi: 10.3390/cancers13092100
pmc: PMC8123630
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncol Rep. 2011 May;25(5):1307-12
pubmed: 21399875
Cancer Cell. 2005 Oct;8(4):323-35
pubmed: 16226707
J Neurooncol. 2007 Sep;84(3):245-8
pubmed: 17415524
J Biol Chem. 2010 Nov 19;285(47):37005-15
pubmed: 20834042
Int J Oncol. 2016 Jan;48(1):110-4
pubmed: 26530115
Int J Oncol. 2015;46(6):2649-55
pubmed: 25825023
Oncotarget. 2014 Jun 15;5(11):3622-35
pubmed: 25004114
Cancer Cell. 2015 May 11;27(5):728-43
pubmed: 25965575
J Neurooncol. 1992 Jul;13(3):283-90
pubmed: 1517804
Nature. 2014 Feb 27;506(7489):451-5
pubmed: 24553141
Eur J Cancer. 2009 Jul;45(10):1815-23
pubmed: 19427780
PLoS One. 2012;7(12):e52113
pubmed: 23284888
BMJ Open. 2019 Sep 17;9(9):e030502
pubmed: 31530611
Neuro Oncol. 2011 Jan;13(1):70-83
pubmed: 20978004
Lipids. 1996 Dec;31(12):1283-8
pubmed: 8972462
J Negat Results Biomed. 2011 May 31;10:7
pubmed: 21627842
Lipids Health Dis. 2015 Feb 18;14:9
pubmed: 25888960
Nat Rev Cancer. 2005 Apr;5(4):275-84
pubmed: 15803154
Neuro Oncol. 2010 Jun;12(6):580-94
pubmed: 20511191
Genes Dev. 2005 May 1;19(9):1028-33
pubmed: 15879553
Mol Cancer Res. 2009 Jun;7(6):765-86
pubmed: 19531565
Nat Protoc. 2007;2(2):329-33
pubmed: 17406593
Cancer Prev Res (Phila). 2014 Aug;7(8):824-34
pubmed: 24866178
Curr Mol Med. 2011 Aug;11(6):503-11
pubmed: 21663587
BMC Cancer. 2008 Sep 30;8:276
pubmed: 18826602
Acta Neuropathol. 2012 Aug;124(2):247-57
pubmed: 22526017
Clin Cancer Res. 2012 Apr 1;18(7):2001-11
pubmed: 22338015
Sci Rep. 2019 Jul 16;9(1):10290
pubmed: 31311995
Pathol Res Pract. 2010 Feb 15;206(2):98-101
pubmed: 19608352
Biomol NMR Assign. 2009 Jun;3(1):89-93
pubmed: 19636954
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Lancet Oncol. 2014 Jan;15(1):35-47
pubmed: 24314616
J Nutr. 2008 Dec;138(12):2510-4
pubmed: 19022980
Breast Cancer Res Treat. 2013 Oct;141(3):341-52
pubmed: 24062211
Acta Neuropathol Commun. 2014 May 30;2:57
pubmed: 24887326
Brain Pathol. 2012 Nov;22(6):848-60
pubmed: 22568867
Adv Biol Regul. 2019 Jan;71:206-218
pubmed: 30245263
Lancet Oncol. 2009 Mar;10(3):258-66
pubmed: 19274783
Clin Cancer Res. 2014 Nov 15;20(22):5630-40
pubmed: 25398846
In Vitro Cell Dev Biol Anim. 2018 Feb;54(2):156-162
pubmed: 29288341